JP2022553908A5 - - Google Patents

Info

Publication number
JP2022553908A5
JP2022553908A5 JP2022521074A JP2022521074A JP2022553908A5 JP 2022553908 A5 JP2022553908 A5 JP 2022553908A5 JP 2022521074 A JP2022521074 A JP 2022521074A JP 2022521074 A JP2022521074 A JP 2022521074A JP 2022553908 A5 JP2022553908 A5 JP 2022553908A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence includes
region amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022521074A
Other languages
English (en)
Japanese (ja)
Other versions
JP7689116B2 (ja
JP2022553908A (ja
Filing date
Publication date
Priority claimed from GB201914747A external-priority patent/GB201914747D0/en
Application filed filed Critical
Publication of JP2022553908A publication Critical patent/JP2022553908A/ja
Publication of JP2022553908A5 publication Critical patent/JP2022553908A5/ja
Priority to JP2025087525A priority Critical patent/JP2025134713A/ja
Application granted granted Critical
Publication of JP7689116B2 publication Critical patent/JP7689116B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022521074A 2019-10-11 2020-10-09 Pd1およびvegfr2二重結合剤 Active JP7689116B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025087525A JP2025134713A (ja) 2019-10-11 2025-05-26 Pd1およびvegfr2二重結合剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1914747.9 2019-10-11
GB201914747A GB201914747D0 (en) 2019-10-11 2019-10-11 PD1 and vegfr2 dual-binding agents
GBGB2013180.1A GB202013180D0 (en) 2019-10-11 2020-08-24 Pd1 and vegfr2 dual-binding agents
GB2013180.1 2020-08-24
PCT/EP2020/078427 WO2021069670A1 (en) 2019-10-11 2020-10-09 Pd1 and vegfr2 dual-binding agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025087525A Division JP2025134713A (ja) 2019-10-11 2025-05-26 Pd1およびvegfr2二重結合剤

Publications (3)

Publication Number Publication Date
JP2022553908A JP2022553908A (ja) 2022-12-27
JP2022553908A5 true JP2022553908A5 (https=) 2023-10-17
JP7689116B2 JP7689116B2 (ja) 2025-06-05

Family

ID=68619556

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022521074A Active JP7689116B2 (ja) 2019-10-11 2020-10-09 Pd1およびvegfr2二重結合剤
JP2025087525A Pending JP2025134713A (ja) 2019-10-11 2025-05-26 Pd1およびvegfr2二重結合剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025087525A Pending JP2025134713A (ja) 2019-10-11 2025-05-26 Pd1およびvegfr2二重結合剤

Country Status (20)

Country Link
US (2) US20240101674A1 (https=)
EP (3) EP4041763B1 (https=)
JP (2) JP7689116B2 (https=)
KR (1) KR20220091490A (https=)
CN (2) CN114981301B (https=)
AU (1) AU2020365021A1 (https=)
CA (2) CA3289307A1 (https=)
DK (1) DK4041763T3 (https=)
ES (1) ES3027238T3 (https=)
FI (1) FI4041763T3 (https=)
GB (2) GB201914747D0 (https=)
HR (1) HRP20250523T1 (https=)
HU (1) HUE071341T2 (https=)
IL (1) IL292158A (https=)
LT (1) LT4041763T (https=)
PL (1) PL4041763T3 (https=)
PT (1) PT4041763T (https=)
RS (1) RS66837B1 (https=)
SI (1) SI4041763T1 (https=)
WO (1) WO2021069670A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
GB201914747D0 (en) 2019-10-11 2019-11-27 Ultrahuman Eight Ltd PD1 and vegfr2 dual-binding agents
CN116143935A (zh) * 2021-11-22 2023-05-23 杭州翰思生物医药有限公司 重组抗体及其应用
WO2024032662A1 (zh) * 2022-08-09 2024-02-15 上海济煜医药科技有限公司 一种靶向pd-1和vegf的抗体及其应用
CN118620082A (zh) * 2023-03-10 2024-09-10 南京维立志博生物科技有限公司 靶向vegf途径和pd-1的双特异性抗原结合蛋白、其组合物和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
RU2689760C2 (ru) * 2012-05-31 2019-05-30 Дженентек, Инк. Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
SG10201804945WA (en) * 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
WO2017055404A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
CN109893654B (zh) * 2017-12-11 2021-07-27 江苏恒瑞医药股份有限公司 Vegfr抑制剂治疗肿瘤的方法
GB201803746D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
GB201803745D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
CN109053895B (zh) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
TWI822897B (zh) 2018-11-06 2023-11-21 大陸商江蘇恆瑞醫藥股份有限公司 一種抗pd-1抗體和法米替尼聯合在製備治療腫瘤的藥物中的用途
GB201914747D0 (en) 2019-10-11 2019-11-27 Ultrahuman Eight Ltd PD1 and vegfr2 dual-binding agents

Similar Documents

Publication Publication Date Title
JP2021519100A5 (https=)
JP2021515541A5 (https=)
JP2022553908A5 (https=)
JP2021515542A5 (https=)
JP2021513323A5 (https=)
JP2022177090A5 (https=)
HRP20200583T1 (hr) Protutijela koja neutraliziraju gp120 i njihova upotreba
TW202126692A (zh) 抗人Claudin18.2抗體及其應用
HRP20250523T1 (hr) Pd1 i vegfr2 sredstva za dvostruko vezivanje
JP2024513921A5 (https=)
JP2021521843A5 (https=)
JP2020531048A5 (https=)
JP2018506961A5 (https=)
JP2020514277A5 (https=)
JP2019500892A5 (https=)
JP2019500891A5 (https=)
JP7679399B2 (ja) 抗flt3抗体及び組成物
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP2021516537A5 (https=)
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
JP2024540148A5 (https=)
JP2020521504A (ja) 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
JP2021534797A5 (https=)
JP2023522730A5 (https=)
JP2023542209A5 (https=)